Rankings
▼
Calendar
TARS Q1 2022 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
TARS
Tarsus Pharmaceuticals, Inc.
$3B
Q1 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$539,000
-98.4% YoY
Gross Profit
$506,000
93.9% margin
Operating Income
-$20M
-3621.7% margin
Net Income
-$20M
-3754.7% margin
EPS (Diluted)
$-0.98
QoQ Revenue Growth
+59.5%
Cash Flow
Operating Cash Flow
-$15M
Free Cash Flow
-$15M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$181M
Total Liabilities
$32M
Stockholders' Equity
$149M
Cash & Equivalents
$175M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$539,000
$33M
-98.4%
Gross Profit
$506,000
$32M
-98.4%
Operating Income
-$20M
$11M
-282.2%
Net Income
-$20M
$10M
-296.8%
Revenue Segments
Collaboration
$539,000
94%
License And Collaboration
$33,000
6%
← FY 2022
All Quarters
Q2 2022 →